Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells

Anticancer Research

Volumn 26, Issue 6 B, 2006, Pages 4143-4148

  Sun, Ying ^a   Eichelbaum, Ehrentraud J ^a   Wang, Hai ^b   Vesely, David L ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Atrial natriuretic peptide; ERK 1 2 kinase; Long acting natriuretic peptide; Natriuretic peptides; Prostate neoplasm

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; LONG ACTING NATRIURETIC PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATRIURETIC FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROSTATE CANCER;

ATRIAL NATRIURETIC FACTOR; CELL LINE, TUMOR; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROSTATIC NEOPLASMS;

EID: 33845930794     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103: 211-225, 2000.
2. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252, 2000.
3. Vesely BA, McAfee Q, Gower WR Jr and Vesely DL: Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 33: 998-1005, 2003.
4. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SM, Gower WR Jr and Vesely DL: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 55: 60-69, 2005.
5. Vesely BA, Alli AA, Song S, Gower WR Jr, Sanchez-Ramos J and Vesely DL: Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 35: 700-710, 2005.
6. Gower WR Jr, Vesely BA, Alli AA and Vesely DL: Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3′5′-cyclic monophosphate. Int J Gastrointestinal Cancer 36: 77-88, 2005.
7. Vesely BA, Fitz SR, Gower WR Jr and Vesely DL: Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett 232: 226-231, 2006.
8. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Alli A, Solivan SM, Gower WR Jr and Vesely DL: Five cardiac hormones decrease the number of human small-cell cancer cells. Eur J Clin Invest 55: 388-398, 2005.
9. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 26: 3217-3222, 2006.
10. Waldman SA, Rapoport RM and Murad F: Atrial natriuretic factor selectively activates membranous guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 259: 14332-14334, 1984.
11. Vesely DL: Signal transduction: Activation of guanylate cyclase-cyclic guanosine-3′-5′ monophosphate system by hormones and free radicals. Am J Med Sci 314: 311-323, 1997.
12. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF: Isolation of a human prostate carcinoma cell line (DU-145). Int J Cancer 21: 274-281, 1978.
13. Vesely DL, Clark LC, Garces AH, McAfee QW, Soto J and Gower WR Jr: Novel therapeutic approach for cancer using four cardiovascular hormones. Eur J Clin Invest 34: 674-682, 2004.